Aileron Therapeutics Inc

NASDAQ:ALRN   3:59:55 PM EDT
1.23
+0.12 (+10.36%)
Other Pre-Announcement

Aileron Therapeutics Says Continues To Expect To Report Preliminary Schedule Optimization Data Of ALRN-6924 In Q4 Of 2020

Published: 09/14/2020 12:15 GMT
Aileron Therapeutics Inc (ALRN) - Aileron Therapeutics - Continues to Expect to Report Preliminary Schedule Optimization Data of Alrn-6924 in Q4 of 2020.
Aileron Therapeutics Inc - Expects to Initiate Phase 1b/2 Clinical Trials in Non-small Cell Lung Cancer in Second Half of 2021.
Aileron Therapeutics Inc - Does Not Currently Plan to Conduct Additional Development of Alrn-6924 in Patients With Sclc.